| Objective: To investigate the expression level of growth hormone receptor (GHR) among gastric cancer and metastasis lymphoid tissue and evaluate the applicable question of recombinant human growth hormone (rhGH) therapy for perioperation period patients with gastric cancer. Methods: We applied rat anti-human growth hormone receptor monoclone antibody and detected GHR expression in gastric cancer and metastasis lymphoid tissue ablated from 48 operative patients by SP ( Streptavidin peroxidase) immunohistochemical method in this experiment. The histopathologic changes were identified by pathology method. The 48 operative patients were in our hospital from January 2003 to May 2004. All the cases chosen were developing gastric cancer. There were 16 cases with middle, 32 cases with low differentiated gastric cancer, 31 cases with lymphnode metastasis and 43 cases with normal gastric mucous membrane. The results were analyzed by X~2 test and PEMS 3.0 software. The GHR expression levels among gastric cancer tissues, metastasis lymphonodes and normal gastric mucous membrane were observed and compared. The relation between the pathology variations and clinical manifestations were analyzed.Results: GHR immunohistochemical positive substance was brown yellow and distributed at cytoplasm cellular membrane clustered or disseminated. The cytoplasm is more than other places. There were 20 positive cases among 48 gastric cancer ones with positive rate 41.7%. There were 13 positive cases among 31 lymphnode metastasis with positive rate 41.9%. There were 41 positive cases among 43 normal gastric mucous membrane ones with positive rate 95.3%. There were significant differences ( P=0.0001 ) of the GHR expression levels between gastric cancer tissue, metastasis lymphnode and normal gastric mucous membrane. The GHRexpression levels between middle and low differential gastric cancer, between male and female cases, among different age groups, between small and large cancer mass were compared and no significant differences were found.Conclusions: GHR expression existed in the middle and low differential developing gastric cancer and lymphnode metastasis. There were significant differences of the GHR expression level among gastric cancer, metastasis lymphnode and normal gastric mucous membrane. The GHR levels of middle-low differential developing gastric cancer cases were not associated to patients' age, sex, pathology differentiation and size of the cancer masses. It can be deduced from the results that if the gastric cancer cells and there GHR have normal biologic function, the usage of rhGH ( recombinanant human growth hormone ) for the gastric cancer patients with perioperation period may improve the growing of cancer cells and the relapse of cancer, so using rhGH for these patients should be cautious about. |
PDF Full Text Request